1
Clinical Trials associated with ARVAC-CG vaccine(Laboratorio Pablo Cassara S.R.L.)Phase 1 Study to Evaluate Safety, Tolerability and Immunogenicity of a New Recombinant Protein-based Vaccine (ARVAC CG) Against Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV-2), in a Population of Healthy Adult Volunteers Previously Vaccinated Against SARS-CoV-2 Virus.
The objective of this clinical trial is to test a new vaccine against SARS-CoV-2 (ARVAC-CG) in healthy adult volunteers, previously vaccinated against the SARS-CoV-2 virus.
The main questions it aims to answer are:
* What is the safety and tolerability profile of the two-dose schedule of this new vaccine?
* What is the immune response after each dose of vaccine Participants will receive two doses of the study vaccine 28 days apart. They will be required to complete a total of 7 safety and immunogenicity follow-up visits over a 1-year period.
100 Clinical Results associated with ARVAC-CG vaccine(Laboratorio Pablo Cassara S.R.L.)
100 Translational Medicine associated with ARVAC-CG vaccine(Laboratorio Pablo Cassara S.R.L.)
100 Patents (Medical) associated with ARVAC-CG vaccine(Laboratorio Pablo Cassara S.R.L.)
100 Deals associated with ARVAC-CG vaccine(Laboratorio Pablo Cassara S.R.L.)